[Disclosure] Samsung Biologics (207940) – Occurrence of Embezzlement and Malfeasance Charges / 2024-02-20
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics has confirmed that the Seoul Central District Prosecutors’ Office filed an appeal against the first-instance acquittal regarding embezzlement and malfeasance charges. 📊 [Key Disclosure Details & Financial Figures] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Monitoring Legal Proceedings Following Prosecution Appeal This disclosure reports…